{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:21:54Z","timestamp":1783506114726,"version":"3.55.0"},"reference-count":8,"publisher":"MDPI AG","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"abstract":"<jats:p>Background: An open-label, noncomparative study was conducted to assess the safety and efficacy of ciclopirox 8% nail lacquer topical solution in patients with type 2 diabetes mellitus.<\/jats:p>\n                  <jats:p>Methods: Forty-nine diabetic patients with distal subungual onychomycosis were treated once daily for 48 weeks with ciclopirox 8% nail lacquer, a topical nail solution approved for the treatment of patients with mild-to-moderate onychomycosis.<\/jats:p>\n                  <jats:p>Results: Treatment resulted in clinical improvement in 63.4% of patients. Most patients (85.7%) had a mycologic outcome of improvement or cure, with 54.3% attaining mycologic cure. Consideration of mycologic and clinical outcomes generated a treatment outcome of improvement, success, or cure in 84.4% of patients. Moreover, patients experienced improvement in the diseased area of the nail (63.4%), nail surface (56.1%), nail color (48.8%), and nail thickness (65.9%). Ciclopirox 8% nail lacquer was safe, with treatment-related adverse events limited to infection in one patient, which resolved in 15 days; the patient completed the study. No treatment-related serious adverse events were observed.<\/jats:p>\n                  <jats:p>Conclusion: Ciclopirox 8% nail lacquer is a safe and effective treatment for distal subungual onychomycosis in patients with type 2 diabetes mellitus receiving insulin or oral hypoglycemic therapy. (J Am Podiatr Med Assoc 97(3): 195\u2013202, 2007)<\/jats:p>","DOI":"10.7547\/0970195","type":"journal-article","created":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T10:07:52Z","timestamp":1396346872000},"page":"195-202","source":"Crossref","is-referenced-by-count":28,"title":["Ciclopirox 8% Nail Lacquer Topical Solution for the Treatment of Onychomycosis in Patients with Diabetes"],"prefix":"10.3390","volume":"97","author":[{"given":"Marc A.","family":"Brenner","sequence":"first","affiliation":[{"name":"Institute for Diabetic Foot Research, Glendale, NY; Department of Podiatry, North Shore University Hospital, North Shore\u2013Long Island Jewish Health System, Manhasset, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Harkless","sequence":"first","affiliation":[{"name":"Department of Orthopedics\/Podiatry, University of Texas Health Science Center, San Antonio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Mendicino","sequence":"first","affiliation":[{"name":"Division of Foot and Ankle Surgery, The Western Pennsylvania Hospital, Pittsburgh, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Page","sequence":"first","affiliation":[{"name":"Arizona Podiatric Medicine Program, Midwestern University\u2013Glendale, Glendale, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","reference":[{"key":"ref271","article-title":"itraconazole package insert Products LP","author":"Sporanox","year":"2004"},{"key":"ref581","first-page":"11","article-title":"Who is at risk for diabetic foot ulceration","volume":"15","author":"Armstrong","year":"1998","journal-title":"Clin Med"},{"key":"ref281","article-title":"terbinafine hydrochloride Tablets package insert Pharmaceuticals","author":"Lamisil","year":"2006","journal-title":"East"},{"key":"ref631","article-title":"itraconazole package insert Products LP","author":"Sporanox","year":"2004"},{"key":"ref671","first-page":"1","article-title":"Pyridones Outstanding Biological Properties in Hydroxy Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis ed by - Verlag","author":"Markus","year":"1999"},{"key":"ref641","article-title":"terbinafine hydrochloride Tablets package insert Pharmaceuticals","author":"Lamisil","year":"2006","journal-title":"East"},{"key":"ref311","first-page":"1","article-title":"Pyridones Outstanding Biological Properties in Hydroxy Pyridones as Antifungal Agents with Special Emphasis on Onychomycosis ed by - Verlag","author":"Markus","year":"1999"},{"key":"ref221","first-page":"11","article-title":"Who is at risk for diabetic foot ulceration","volume":"15","author":"Armstrong","year":"1998","journal-title":"Clin Med"}],"container-title":["Journal of the American Podiatric Medical Association"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/97\/3\/195\/1413089\/0970195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/japma\/article-pdf\/97\/3\/195\/1413089\/0970195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:11:06Z","timestamp":1783505466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1930-8264\/97\/3\/195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,1]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.7547\/0970195","relation":{},"ISSN":["8750-7315","1930-8264"],"issn-type":[{"value":"8750-7315","type":"print"},{"value":"1930-8264","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,1]]}}}